Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Glucocorticoids and recombinant growth hormone
8 evidence topics · 10 sources
Glucocorticoids for refractory hypoglycemia in insulinoma: ENETS 2023 guidance
Glucocorticoids in insulinoma: dose and adverse effects
“Glucocorticoids are sometimes used to control the hypoglycemia but their chronic use poses a significant risk for side effects (eg, weight gain, neuropsychiatric disturbances, hypertension, secondary [opportunistic] infections).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Glucocorticoids inhibit insulin release and increase peripheral insulin resistance and have been used in the management of refractory hypoglycaemia at a low dose (prednisolone 2.5 mg daily, dexamethasone 0.5−4 mg) where other agents have been ineffective” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Glucocorticoids and recombinant growth hormone in NICTH: clinical review
“In such cases, we suggest consideration of local antitumor therapies for disease control and trial of glucocorticoids alone or in combination with GH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Diazoxide and octreotide have no role in NICTH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Glucocorticoids (including dexamethasone, hydrocortisone, prednisolone, and prednisone, typically in doses equivalent to prednisone 30–60 mg/d) are the most extensively described medical therapy for NICTH” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recombinant human GH (rhGH) at supraphysiological doses of 3–12 mg daily has been successful in many cases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additionally, we propose that cost could be a limiting factor, especially for long-term therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Combination therapy was successful (including freedom from iv glucose or dextrose) in multiple cases where monotherapy with either failed” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although there are no randomized controlled trials to guide therapy, ample case reports and series are available in the literature over the past quarter century.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Glucocorticoid dose threshold and reversibility in NICTH: case series
“Therapeutic treatment with glucocorticoids confirmed previous studies showing the suppressive effect on tumour (big) IGF-II production.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The present data show that the effect was dose-dependent and reversible if doses were below a critical level.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This effectiveness was only achieved when the dose exceeded a threshold level specific to the patient.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Glucocorticoids compared with growth hormone in NICTH: effect on big IGF-II
“Two groups each of 4 patients, all diagnosed as cases of NICTH, were treated with either hGH or glucocorticoids.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Glucocorticoid therapy has been demonstrated to consistently reverse the biochemical abnormalities caused by tumour-derived big IGF-II compared with the potentially adverse stimulatory effects of hGH treatment in causing increases in serum levels of big IGF-II.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Glucocorticoid minimum effective doses and growth hormone combination in IGF-2-mediated hypoglycemia
“The minimum effective dose in one review of NICTH with solitary fibrous tumours was 25 mg/day for prednisolone, 32 mg/day for methylprednisolone, and 2 mg/day for dexamethasone” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recurrent hypoglycemia is also seen when the glucocorticoid dose is reduced below the aforementioned thresholds, limiting their long-term utility” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The combination of rGH with glucocorticoids at low doses, as in case 2, is an effective regimen with minimal adverse effects in patients with inoperable tumours” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When the tumour is unresectable, moderate-dose glucocorticoids, low-dose glucocorticoids in combination with recombinant growth hormone, and pasireotide are medical therapies with promising results in controlling NICTH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Frequency of glucocorticoid use in IGF-2-mediated hypoglycemia: systematic review of 233 patients
“Medication therapy with corticosteroids, octreotide and diazoxide was used in 91 (39.1%), 18 (7.7%) and 16 (6.9%) cases, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Management such as octreotide, corticosteroids, diazoxide, embolization, radiotherapy and surgical resection have disparate success rates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote